Small study explores real-world switch to riociguat for tough PAH cases
NCT ID NCT07374302
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This observational study will review medical records of 15 adults with pulmonary arterial hypertension (PAH) who switched from one medication (a PDE5 inhibitor) to riociguat while already on triple therapy. The goal is to see if this switch improves exercise ability, symptoms, and blood markers at 6 months. Because it is a retrospective chart review, no new treatments are given, and the results will only describe what happened in routine care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
riociguat
What this could lead to
If results are positive, this could suggest that switching to riociguat is a useful option for PAH patients not doing well on standard triple therapy.
What could go wrong
This is a very small (15 people), single-center, retrospective study, so results may not apply widely. It only observes routine care, so it cannot prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••